Daniel Meretz

Daniel Meretz

Auto-generated profile, based on publicly available information

Daniel Meretz

Department of Cardiology, University Hospital Heart Centre Brandenburg, Brandenburg Medical School (MHB) Theodor Fontane, Neuruppin, Germany (M.S., D.M., A.H.-F., C.G., M.B., V.M., C.B.).

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2024 in Circulation: Cardiovascular Quality and Outcomes
Verified
Journal Article
Closed access
MSMartin Seifert
Martin Seifert
DMDaniel Meretz
Daniel Meretz
AHAnja Haase-Fielitz
Anja Haase-Fielitz
CGChristian Georgi
Christian Georgi
MBMarwin Bannehr
Marwin Bannehr
CBChristian Butter
Christian Butter
BACKGROUND: Arrhythmia recurrence after pulmonary vein isolation (PVI) is common. We conducted a multicenter, randomized trial to determine the impact of increased physical activity on atrial fibrillation recurrence after PVI. METHODS: From 2018 to 2020, we randomly assigned 200 patients with atrial fibrillation to the ACTION or NO-ACTION group in 4 different centers in the local country of Brandenburg, Germany. Patients were eligible if they were scheduled to undergo PVI, aged ≥50 to ≤77 years, body mass index ≥23 to ≤35 kg/m 2 , and accepted wearing an activity tracker allowing 24-hour activity monitoring via mobile app. Patients in the ACTION group were actively remote-controlled via transmitted activity data by a physiotherapist, and individual motivational interviewing call sessions were scheduled with each ACTION patient every 2 weeks. The primary end point was the composite of recurrence of any atrial arrhythmia >30 seconds, additional ablation procedure, cardioversion, and new onset of antiarrhythmic drugs earliest after 90 days after index PVI over 12 months. RESULTS: Overall, the median age of patients was 66 (interquartile range, 61–71) years, 33.5% were women, and 52% had persistent atrial fibrillation. The number of steps per day increased in both groups of patients from baseline to 12 months ( P <0.001). The absolute increase in steps per day did not differ between patients in the ACTION group with +3205 steps (597–4944) compared with those in the NO-ACTION group +2423 steps (17–4284), P =0.325. Unadjusted intention-to-treat analysis showed no difference in the primary composite end point in the ACTION group (27.3%) versus the NO-ACTION group (32.7%), P =0.405. CONCLUSIONS: Physical activity improved in patients after PVI. The present randomized controlled trial shows that activity tracker and motivational calls to increase physical activity versus activity tracker alone did not reduce the occurrence of the primary composite end point of atrial fibrillation recurrence or the absolute increase in steps per day. REGISTRATION: URL: https://www.cochranelibrary.com ; Unique identifier: DRKS00012914.

1 January 2025 in Journal of Interventional Cardiology
Verified
Journal Article
Open access
DMDaniel Meretz
Daniel Meretz
MSMartin Seifert
Martin Seifert
AHAnja Haase-Fielitz
Anja Haase-Fielitz
CGChristian Georgi
Christian Georgi
MBMarwin Bannehr
Marwin Bannehr
CBChristian Butter
Christian Butter
Background: Gender differences exist in atrial fibrillation (AF) regarding epidemiology, mechanisms, management, and outcomes. There are limited data regarding gender‐specific outcomes after pulmonary vein isolation (PVI) including AF recurrence, physical activity, and health‐related quality of life. Methods: In this secondary analysis of a randomized controlled trial (BE‐ACTION study: investigating 200 patients with paroxysmal or persistent AF undergoing PVI), a gender‐specific analysis of the primary endpoint (recurrence of atrial arrhythmia > 30s, additional ablation procedure, or new onset of antiarrhythmic drugs) was performed. Quality of life was assessed using the AFEQT and SF‐36 questionnaires, while physical activity was measured via step counts recorded at baseline, 6 months, and 12 months. The Mann–Whitney U test and Fisher exact test were used to compare continuous and categorical variables, respectively. Results: 33.5% were women. Women and men were comparable in demographics, comorbidities, and steps per day before and after PVI. There was no statistically significant difference in the primary composite endpoint between women (37.3%) and men (25.6%) ( p = 0.085). Before PVI, women had lower quality of life scores than men (median AFEQT scores: 43.5 points [25 th to 75 th percentiles 25.9–63.9] vs. 62.0 points [47.2–76.4], respectively, p < 0.001) as well as in the physical (40.22 points [33.98–46.69] vs. 46.30 points [39.21–51.60], p = 0.002) and mental domains (42.33 points [27.34–51.59] vs. 49.59 points [36.02–55.64], p = 0.001) of the SF‐36 questionnaire. The overall improvement in the quality of life was significant for both men and women ( p < 0.001). Using AFEQT, women exhibited lower quality of life scores compared to men at 6 months post‐PVI ( p = 0.001); however, this difference was no longer statistically significant at 12 months ( p = 0.077). Conclusion: These data emphasize the importance of AF recurrence after PVI and motivate future research to explore the causes and clinical consequences of a gender gap in quality of life in women after PVI. Trial Registration: WHO International Registry of Clinical Trials: DRKS00012914

10 September 2026 in JMIR Cardio
Verified
Journal Article
Open access
RFRobert Fenske
Robert Fenske
DRDenise Rossa
Denise Rossa
CBChristian Butter
Christian Butter
FMFelix Muehlensiepen
Felix Muehlensiepen
JNJonathan Nübel
Jonathan Nübel
AHAnja Haase-Fielitz
Anja Haase-Fielitz
Background: Atrial fibrillation (AF) is a major contributor of thromboembolic stroke. However, early detection remains challenging and is severely hindered by structural limitations in health care infrastructure. While current clinical guidelines recognize a 30-second single-lead electrocardiogram (ECG) as a standard diagnostic tool, the actual deployment and real-world utility of mobile screening technologies across health care settings remain poorly understood. Objective: The primary objective of this study was to evaluate the real-world feasibility of a mobile single-lead ECG for the detection of AF in routine inpatient and outpatient settings. Feasibility was evaluated by the proportion of successfully completed recordings, patient acceptance, and the occurrence and characteristics of technical challenges during deployment. Methods: This multicenter, cross-sectional pragmatic implementation study enrolled patients across 3 university hospitals and 3 primary care practices. Screening was performed using an US Food and Drug Administration (FDA)–approved single-lead ECG device (AliveCor KardiaMobile). Patients with an automated device reading indicating “Possible AF” and no prior diagnosis of AF underwent a confirmatory 12-lead ECG. Patient awareness and acceptance were evaluated using an exploratory, descriptive questionnaire. Results: A total of 237 patients were enrolled (194 inpatients and 43 outpatients). The device algorithm provided an automatic interpretation in 95.3% (41/43) of the outpatients and 85.6% (166/194) of inpatients, resulting in an overall automated detection of AF in 21.5% (51/237) of the cohort. The algorithm identified newly suspected AF in 1.7% (4/237) of patients without a prior AF diagnosis. Of these, 1 case underwent same-day confirmatory 12-lead ECG and was confirmed as AF. Technical challenges occurred in 16.0% (38/237) of all recordings, with a numerical higher rate observed in the inpatient setting (34/194, 17.5% vs 4/43, 9.3% in outpatients; P =.25). Only 6.3% (15/237) of patients reported regular use of telemedicine applications. Conclusions: Mobile single-lead ECG screening is feasible in routine inpatient and outpatient settings and identified a substantial prevalence of AF, which increased with age. The high detection rate underscores the potential of wearable ECG devices to facilitate early detection of AF. However, the absence of systematic confirmatory ECG testing and limited patient engagement with telemedicine applications highlight challenges in real-world implementation.